A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions in the United States and Japan. Thirty-three (56%) of the patients received ATO-based therapy prior to stem cell collection. Delayed neutrophil engraftment occurred in 10 patients (17%): 9 of the 10 patients (90%) received prior ATO (representing 27% of all ATO-treated patients), compared with 1 of the 10 patients (10%) not previously treated with ATO (representing 4% of all ATO-naïve patients; P o0.001). Compared with ATO-naïve patients, ATO-treated patients experienced significantly longer times to ANC recovery (median 12 days vs 9 days, P o 0.001). In multivariate analysis, the only significant independent predictor of delayed neutrophil engraftment was prior treatment with ATO (hazard ratio 4.87; P o 0.001). Of the available stem cell aliquots from APL patients, the median viable post-thaw CD34+ cell recovery was significantly lower than that of cryopreserved autologous stem cell products from patients with non-APL AML. Our findings suggest that ATO exposure prior to CD34+ cell harvest has deleterious effects on hematopoietic recovery after autologous HSCT.
INTRODUCTION
Acute promyelocytic leukemia (APL) accounts for~5-8% of adult AMLs, representing 600-800 new cases annually in the United States. [1] [2] [3] Although CR rates may exceed 90% with upfront therapy for APL, as many as 15-30% of patients will relapse after initially receiving ATRA-and cytotoxic chemotherapy-based therapies. [4] [5] [6] [7] [8] [9] Arsenic trioxide (ATO) is a more recent addition to the APL therapeutic arsenal. Initially proven effective in achieving remissions in relapsed APL, ATO plus ATRA was recently demonstrated to be not-inferior to ATRA plus chemotherapy in the front-line setting for low-and intermediate-risk patients. 10, 11 For APL patients who relapse and subsequently attain a CR2, and for some APL patients who are deemed high-risk for relapse in CR1, autologous hematopoietic SCT (HSCT) continues to have an important therapeutic role. [12] [13] [14] [15] Little is known about the impact of ATO on subsequent autologous HSCT, but two cases of delayed hematopoietic recovery in patients treated with ATO have been reported. 16 To better understand the impact of ATO therapy on hematopoietic recovery, we retrospectively reviewed the histories of all patients who underwent autologous HSCT for APL at our institution since 1994. We additionally included data from all APL patients who underwent autologous HSCT in the only published prospective trial of ATO therapy prior to autologous HSCT by the Japan Adult Leukemia Study Group (JALSG). 17 We identify an association between ATO-based APL therapy and delayed hematopoietic recovery following autologous HSCT.
PATIENTS AND METHODS
We retrospectively analyzed the medical records of 35 consecutive adult APL patients (age ⩾ 18 years) who underwent autologous HSCT at the University of California, San Francisco (UCSF) Medical Center between January 1994 and July 2012. A contemporaneous control cohort of patients who underwent autologous HSCT for non-APL AML in CR1 or CR2 was included for analysis of neutrophil and plt engraftment. 
Definition of outcomes
Neutrophil engraftment was defined as the first of 3 consecutive days with an ANC4500 per μl. To facilitate merging the UCSF and JALSG data sets, plt engraftment was defined as the first of 3 consecutive days during hospitalization with an unsupported plt count 430 000 per μl. If patients did not achieve plt engraftment by the end of their transplant hospitalization, the date of engraftment was defined as the first unsupported post-hospitalization plt count 430 000 per μl. For the purposes of statistical comparison, delayed hematopoietic recovery was defined as requiring 414 days after stem cell infusion to achieve an ANC4500 per μl, which was 2 s.d. above the mean number of days to achieve neutrophil engraftment in patients not receiving ATO therapy. Similarly, delayed plt recovery was defined as requiring 490 days after HSCT to achieve an unsupported plt count 430 000 per μl.
CD34 viability assays
Cryopreserved cell samples were thawed at 37 o C and immediately resuspended in a 1:1 dextran 40/albumin solution. Cell suspensions were equilibrated at room temperature for 1 min and an aliquot was then stained for viability using Beckman Coulter antibodies (Beckman Coulter, Brea, CA, USA) to CD34 (phycoerythrin-conjugated) and 7-aminoactinomycin D. Cells were interrogated using a Beckman Coulter FC500 (Beckman Coulter) with ⩾ 100 000 events collected for each sample. Analysis was performed using CXP cytometer software (Beckman Coulter).
Statistical analysis
Normally distributed continuous data are reported as mean (± s.d.), and time data are reported as median (range). Categorical data are reported as frequency (%). Multivariate analyses were performed using SAS 9.1.3 software (SAS Institute Inc., Cory, NC, USA). A P-value of o 0.05 was considered significant. Kaplan-Meier and cumulative incidence curves were generated using GraphPad Prism (GraphPad Software, La Jolla, CA, USA) and statistical differences were assessed via Fisher's exact, Log-Rank and Wilcoxon analyses.
RESULTS

Patient characteristics
Thirty-five APL patients (15 men and 20 women) underwent a total of 36 autologous HSCTs in the UCSF cohort (Table 1) . One patient relapsed 43 years after his first autologous HSCT and received a second autologous HSCT. One ATO-treated patient was excluded from analysis due to contamination of the initial CD34+ cell collection with Candida krusei. In the JALSG cohort, 23 APL patients (13 men and 10 women) underwent autologous HSCT.
Twenty-four transplants (41%) were performed for patients in CR1 and 35 (59%) for patients in CR2. All transplants in the JALSG cohort were performed for patients in CR2 vs 12 of 36 transplants (33%) in the UCSF cohort. Thirty-three of the 59 transplants (56%) were performed for patients who received ATO-based therapy prior to autologous stem cell collection.
A significantly higher proportion of patients who received ATO were transplanted in CR2 (94 vs 15%, P o0.001). There were otherwise no significant differences in clinical characteristics or risk features between the ATO-treated and the ATO-naïve transplant recipients (Table 1) . Patients in the UCSF cohort were infused a mean CD34+ cell dose of 26 ×10 6 per kg (range 7.5-148; data unavailable for the JALSG cohort).
Delayed hematopoietic recovery Compared with ATO-naïve patients, ATO-treated patients experienced significantly longer time to ANC recovery in univariate analysis (median 12 vs 9 days, P o0.001) (Figure 1a ). Plt recovery was not significantly delayed in univariate analysis but showed a trend toward longer time-to-engraftment in the ATO-treated group (median 18 vs 13 days, P = 0.26) (Figure 1b ). In the UCSF cohort, ATO-treated patients required significantly longer transplant hospitalizations (median 30 vs 25 days, P o 0.001; data unavailable for the JALSG cohort) (Figure 1c ).
Ten cases (17%) of delayed neutrophil engraftment were identified, five (14%) in the UCSF cohort and five (22%) in the JALSG cohort. Nine of the 33 patients (27%) who received prior ATO experienced delayed neutrophil engraftment, compared with 1 of the 26 patients (3.8%) not previously treated with ATO (P = 0.032). In a multivariate analysis including remission status (CR1 vs CR2) and conditioning regimen (UCSF vs JALSG), the only significant independent predictor of delayed neutrophil engraftment was prior treatment with ATO (hazard ratio 4.86, confidence interval 1.96-12.11, P o0.001). Delayed plt recovery was independently predicted by either prior ATO-based therapy (hazard ratio 4.13, confidence interval 1.60-10.68, P = 0.004) or by undergoing transplant in Japan (hazard ratio 2.71, confidence interval 1.11-6.61, P = 0.028). In multivariate analysis (Table 2) , remission status was not a predictor of time to hematopoietic recovery. Similarly, neither the ATO dose per kilogram, nor the CD34+ cell dose infused (data available for UCSF cohort only) significantly impacted hematopoietic recovery in univariate analysis.
To further explore whether delayed hematopoietic recovery may have been attributable to a higher proportion of ATO-treated patients undergoing transplant in CR2, we evaluated the time to hematopoietic recovery of 65 consecutive non-APL AML patients who underwent autologous stem cell transplant in CR1 (n = 51) or CR2 (n = 14) at UCSF. There was no significant difference in the median time to neutrophil engraftment (median 11 days for both; P = 0.95) (Supplementary Figure 1A) or plt engraftment (median 19 vs 16 days, P = 0.10) (Supplementary Figure 1B) .
Post-thaw CD34+ cell viability Cryopreserved aliquots from the initial stem cell collection were available for seven patients in the UCSF cohort (four ATO-treated and three ATO-naïve) to test post-thaw CD34+ cell viability. In the seven APL patient samples, the median post-thaw CD34+ cell viability was 65% (range 4.2-76%). The median CD34+ cell viability in the four ATO-treated patients was not significantly different than the three ATO-naïve patient samples. By comparison, however, median CD34+ cell viability was significantly higher (81%, range 49-92%; P = 0.005) in a random selection of 15 cryopreserved autologous stem cell products from patients with non-APL AML (Figure 2 ). CD34+ cell yield prior to cryopreservation was not different between ATO-treated and ATO-naïve patients.
Clinical outcomes
With median follow-up of 4.5 years (range 0.2-18), 7 of the 58 patients have died (12%; 5 from relapsed disease). Nine of the 10 patients (90%) who experienced delayed neutrophil engraftment remain alive and 28 of 30 patients (93%) with follow-up longer than 5 years after autologous HSCT remain alive. Median relapse-free (RFS) and OS have not been reached, although statistically the RFS and OS were both shorter in patients receiving ATO prior to stem cell collection (Figure 3) , likely reflecting the higher proportion of ATO-treated patients being transplanted in CR2.
In the UCSF cohort, delayed neutrophil engraftment was clinically significant in all cases. Four patients-all of whom were treated with ATO-required additional stem cell infusions, and all required significantly more RBC (median 6 vs 2 units, P = 0.001) and plt transfusions (median 5 vs 3 units, P = 0.022), as well as longer hospitalizations (median 30 vs 25 days, P o0.001).
DISCUSSION ATO is increasingly used as both front-line and as salvage therapy for APL. In this study, we analyzed the impact of pre-transplant ATO-based therapy on subsequent hematopoietic recovery after autologous HSCT. We found a significant association between ATO-based therapy and delayed hematopoietic recovery following Abbreviations: ATO = Arsenic trioxide; CI = confidence interval; JALSG = Japan Adult Leukemia Study Group; RR = recovery rate. autologous HSCT. This was associated with an increased need for transfusion support and longer hospitalizations. We hypothesize that impaired post-thaw CD34+ cell viability in patients with APL may interact with prior ATO exposure, subsequently leading to delayed post-transplant hematopoietic recovery. APL cells are uniquely sensitive to the ability of ATO to promote differentiation, inhibit proliferation and induce apoptosis via its effect on the PML-RARα transcript. 18 These effects are dosedependent in vitro, with induction of apoptosis via both PML-RARα-dependent and -independent mechanisms at high concentrations. 19 PML-RARα-independent mechanisms have the potential for off-target effects that may underlie the delay in normal hematopoietic recovery seen in our study. For example, in APL NB4 cells in vitro, this includes a H 2 O 2 -dependent pathway that results from sensitivity of the intracellular glutathione redox system to ATO. 20 In myeloma cell lines, anti-proliferative effects of ATO may be mediated through inhibition of the transcription factor nuclear-factor-kappa B and interference with IL-6 activity. 21 In vitro exposure of non-APL leukemic cell lines to ATO has antiangiogenic properties, inhibiting vascular endothelial growth factor production and preventing capillary growth. 22 The biological mechanism of delayed hematopoietic recovery in our study warrants further investigation.
The present study has several limitations. As a retrospective study, the ability to further define the biologic mechanism of delayed hematopoietic recovery was limited by the availability of stored stem cell aliquots. In addition, as a merged data set from multiple centers, institutional protocols for stem cell collection, storage and transplantation differed slightly. Nonetheless, in multivariate analysis, delayed neutrophil engraftment was not significantly associated with institution.
In summary, this study confirms an association between ATO exposure prior to autologous stem cell harvest and delayed hematopoietic recovery after autologous HSCT for APL. Our study identified impaired CD34+ cell viability in patients with APL relative to non-APL AML, suggesting that APL autografts may be vulnerable to detrimental functional impacts of prior ATO exposure, although neither a clear causal relationship nor a specific biologic mechanism is yet established. Because of increasing usage of ATO in front-line APL therapy, larger studies are warranted to validate these findings and to determine the potential mechanism of delayed hematopoietic recovery after autologous HSCT and whether it can be mitigated. OS was decreased in ATO-exposed vs non-ATO-exposed patients, but is likely confounded by a higher proportion of patients transplanted in CR2 in the ATO-exposed group. Kaplan-Meier curves are truncated at 6 years for improved visualization.
